Mara Goldstein is a Managing Director serving as the Director of Research and Senior Biotechnology Analyst with Clear Street LLC beginning in early 2024, where she is leading the build-out of the equity research practice for the firm. Mara's experience in equity research spans multiple financial service firms, working in institutions in process of growth and change.

Prior to joining Clear Street, Mara was a senior biotechnology analyst with Mizuho Securities, overseeing the firm's coverage of oncology-focused equities. Before joining Mizuho in 2018, Mara worked at Cantor Fitzgerald, where she oversaw the build-out of the healthcare equity research group as Head of Healthcare and biotechnology analyst, from 2011-2015, before assuming the additional role of Director of Research in 2015. Mara also worked at Thomson

Reuters, initially as head of the healthcare practice for Reuters Insight, a bespoke research team, and later as head of research, from 2005-2008. Prior to that, Mara was a senior pharmaceutical analyst and Executive Director with CIBC Oppenheimer (now Oppenheimer) from 1998-2005. an associate at Alex. Brown & Sons (ahead of its acquisition by Bankers Trust) and a research assistant with CS First Boston. Mara frequently makes appearances on CNBC,

Bloomberg News, and has been quoted in the Wall Street Journal, New York Times, Financials Times, US News & World Report, and other publications. Mara received an undergraduate degree from Purdue University.

?